Table of Content

1. Introduction to US Biosimilar Insulin Market
1.1 Overview
1.2 Current Market Scenario


2. US Biosimilar Insulin Market Opportunity Assessment
2.1 Overall Market Opportunity
2.2 Opportunity by Product Type


3. Semglee - First FDA Approved Interchangeable Biosimilar Insulin
3.1 Overview
3.2 Dosages & Price Analysis
3.3 Sales Forecast


4. US Biosimilar Insulin Market - Cost Comparison
4.1 Semglee v/s Lantus
4.2 Semglee v/s Basaglar
4.3 Semglee v/s Toujeo


5. US Biosimilar Insulin Market - Clinical Insight


6. US Biosimilar Insulin Market Dynamics
6.1 US Biosimilars Insulin Drivers Market
6.2 Challenges for US Biosimilar Insulin Market


7. US Biosimilar Insulin Market Future Outlook


8. Competitive Landscape
8.1 Biocon
8.2 Boehringer Ingelheim
8.3 Eli Lily
8.4 Gan & Lee Pharmaceuticals
8.5 Harvest Moon Pharmaceuticals
8.6 HEC Pharma
8.7 Mylan
8.8 Samsung Bioepis
8.9 Sanofi
8.10 Wockhardt



List of Figures

Figure 1-1: US – Estimated Diabetic Population (Million), 2019, 2025, 2030 & 2045
Figure 1-2: US – Undiagnosed & Diagnosed Diabetic Population (Million), 2019
Figure 1-3: US – Undiagnosed & Diagnosed Diabetic Population (%), 2019
Figure 1-4: US – Estimated Diabetic Prevalence Rate (%), 2019, 2025, 2030 & 2045
Figure 1-5: US – Number of Insulin Users (Million), 2020 & 2030
Figure 1-6: US – Total Diabetic Population v/s Insulin Users (Million), 2020
Figure 1-7: US – Total Diabetic Population v/s Insulin Users (%), 2020
Figure 1-8: US – Diabetes Drug Market Size by Products (US$ Billion), 2020
Figure 1-9: US – Diabetes Drug Market Size by Products (%), 2020

Figure 2-1: US – Diabetes Drug Market Opportunity (US$ Billion), 2021–2026
Figure 2-2: US – Insulin Market Opportunity (US$ Billion), 2021–2026
Figure 2-3: US – Biosimilar Insulin Market Opportunity (US$ Million), 2021–2026
Figure 2-4: US – Number of Insulin Users (Million), 2020 - 2026
Figure 2-5: US – Number of Biosimilar Insulin Users by 10% of Total Insulin Users (Million), 2020 - 2026
Figure 2-6: US – Number of Biosimilar Insulin Users by 20% of Total Insulin Users (Million), 2020 - 2026
Figure 2-7: US – Number of Biosimilar Insulin Users by 30% of Total Insulin Users (Million), 2020 - 2026
Figure 2-8: US – Number of Biosimilar Insulin Users by 40% of Total Insulin Users (Million), 2020 - 2026
Figure 2-9: US – Number of Biosimilar Insulin Users by 50% of Total Insulin Users (Million), 2020 - 2026
Figure 2-10: US – Biosimilar Insulin Market Opportunity by 10% Acceptance Rate (US$ Million), 2021–2026
Figure 2-11: US – Biosimilar Insulin Market Opportunity by 20% Acceptance Rate (US$ Million), 2021–2026
Figure 2-12: US – Biosimilar Insulin Market Opportunity by 30% Acceptance Rate (US$ Billion), 2021–2026
Figure 2-13: US – Biosimilar Insulin Market Opportunity by 40% Acceptance Rate (US$ Billion), 2021–2026
Figure 2-14: US – Biosimilar Insulin Market Opportunity by 50% Acceptance Rate (US$ Billion), 2021–2026

Figure 2-15: US – Insulin Glargine Biosimilar Market Opportunity (US$ Million), 2021–2026
Figure 2-16: US – Insulin Lispro Biosimilar Market Opportunity (US$ Million), 2023–2026
Figure 2-17: US – Insulin Aspart Biosimilar Market Opportunity (US$ Million), 2023–2026

Figure 3-1: US – Semglee FDA Approval History (Year)
Figure 3-2: US – Price for 10ml Vial & Price Per ml of Semglee Subcutaneous Solution (US$), August’2021
Figure 3-3: US – Price for 5 Prefilled Pens, Single Pen & Price Per ml of Semglee Subcutaneous Solution (US$), August’2021
Figure 3-4: US – Semglee Sales Forecast (US$ Million), 2021-2026

Figure 4-1: US – Price Comparison for 10ml Vial of Lantus & Semglee (US$), August’2021
Figure 4-2: US – Price Comparison for 5 Prefilled Pens of 3ml Lantus & Semglee (US$), August’2021
Figure 4-3: US – Monthly Treatment Cost Comparison Lantus v/s Semglee (US$), August’2021
Figure 4-4: US – Price Comparison for 5 Prefilled Pens of 3ml Basaglar & Semglee (US$), August’2021
Figure 4-5: US – Monthly Treatment Cost Comparison Basaglar v/s Semglee (US$), August’2021
Figure 4-6: US – Cost per ml Comparison of Toujeo Solostar v/s Semglee (US$), August’2021
Figure 4-7: US – Cost per ml Comparison of Toujeo Max Solostar v/s Semglee (US$), August’2021

Figure 5-1: US – Number of Biosimilars in Clinical Trial by Phase
Figure 5-2: US – Number of Biosimilars in Clinical Trial by Phase

Figure 6-1: US Insulin Biosimilars Market Drivers
Figure 6-2: Challenges for US Insulin Biosimilars Market